Improving Risk Assessment in Clinical Trials: Toward a Systematic Risk-Based Monitoring Approach

Show simple item record

dc.identifier.uri Fneish, Firas Schaarschmidt, Frank Fortwengel, Gerhard 2022-07-07T08:09:58Z 2022-07-07T08:09:58Z 2021
dc.identifier.citation Fneish, F.; Schaarschmidt, F.; Fortwengel, G.: Improving Risk Assessment in Clinical Trials: Toward a Systematic Risk-Based Monitoring Approach. In: Current Therapeutic Research - Clinical and Experimental 95 (2021), 100643. DOI:
dc.description.abstract Regulatory authorities have encouraged the usage of a monitoring (RBM) system in clinical trials before trial initiation for detection of potential risks and inclusion of a mitigation plan in the monitoring strategy. Several RBM tools were developed after the International Council for Harmonization gave sponsors the flexibility to initiate an approach to enhance quality management in a clinical trial. However, various studies have demonstrated the need for improvement of the available RBM tools as each does not provide a comprehensive overview of the characteristics, focus, and application. This research lays out a rationale for a risk methodology assessment (RMA) within the RBM system. The core purpose of RMA is to deliver a scientifically based evaluation and decision of any potential risk in a clinical trial. Thereby, a monitoring plan can be developed to elude prior identified risk outcome. To demonstrate RMA's theoretical approach in practice, a Shiny web application (R Foundation for Statistical Computing) was designed to describe the assessment process of risk analysis and visualization tools that eventually aid in focusing monitoring activities. RMA focuses on the identification of an individual risk and visualizes its weight on the trial. The scoring algorithm of the presented approach computes the assessment of the individual risk in a radar plot and computes the overall score of the trial. Moreover, RMA's novelty lies in its ability to decrease biased decision making during risk assessment by categorizing risk influence and detectability; a characteristic pivotal to serve RBM in assessing risks, and in contributing to a better understanding in the monitoring technique necessary for developing a functional monitoring plan. Future research should focus on validating the power of RMAs to demonstrate its efficiency. This would facilitate the process of characterizing the strengths and weaknesses of RMA in practice. © 2021 The Author(s) eng
dc.language.iso eng
dc.publisher Amsterdam [u.a.] : Elsevier Science
dc.relation.ispartofseries Current Therapeutic Research - Clinical and Experimental 95 (2021)
dc.rights CC BY-NC-ND 4.0 Unported
dc.subject Clinical trials eng
dc.subject ICH-GCP eng
dc.subject Mitigation plan eng
dc.subject Risk methodology assessment eng
dc.subject Risk-based monitoring eng
dc.subject algorithm eng
dc.subject decision making eng
dc.subject human eng
dc.subject risk assessment eng
dc.subject telecommunication eng
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Improving Risk Assessment in Clinical Trials: Toward a Systematic Risk-Based Monitoring Approach
dc.type Article
dc.type Text
dc.relation.essn 1879-0313
dc.bibliographicCitation.volume 95
dc.bibliographicCitation.firstPage 100643
dc.description.version publishedVersion
tib.accessRights frei zug�nglich

Files in this item

This item appears in the following Collection(s):

Show simple item record


Search the repository


My Account

Usage Statistics